The current stock price of BIVV is 104.98 null. In the past month the price increased by 1.67%. In the past year, price increased by 98.11%.
ChartMill assigns a technical rating of 8 / 10 to BIVV. When comparing the yearly performance of all stocks, BIVV is one of the better performing stocks in the market, outperforming 97.96% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to BIVV. BIVV has only an average score on both its financial health and profitability.
Over the last trailing twelve months BIVV reported a non-GAAP Earnings per Share(EPS) of 3.2774. The EPS decreased by -19.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 30.43% | ||
| ROA | 21.97% | ||
| ROE | 39.62% | ||
| Debt/Equity | 0 |
Bioverativ Inc. is a biotechnology company. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ Inc. is based in Waltham, United States.
BIOVERATIV INC
225 2ND AVENUE
WALTHAM MA 02451
CEO: John G. Cox
Phone: 781-663-4400
Bioverativ Inc. is a biotechnology company. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ Inc. is based in Waltham, United States.
The current stock price of BIVV is 104.98 null. The price increased by 0.32% in the last trading session.
BIVV does not pay a dividend.
BIVV has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BIVV.
BIOVERATIV INC (BIVV) has a market capitalization of 11.36B null. This makes BIVV a Large Cap stock.